Evidence that the protein phosphatase activity of PTEN contributes to embryonic development and tumour suppression in mice
Priyanka TibarewaliD, Laura SpinelliiD, Nisha Kriplani, Helen M. WiseiD, Nadège PoncetiD, Giulia Marzano, Karen E. AndersoniD, Katarzyna M. GrzesiD, Zofia VaryovaiD, Mahreen AdiliD, C. Peter Downes, Phillip T. HawkinsiD, Len StephensiD, Kate G. StoreyiD, Doreen Ann CantrelliD, Bart VanhaesebroeckiD, Nicholas R. LeslieiD
Abstract
PTEN (phosphatase and tensin homologue deleted on chromosome ten) is a tumour suppressor, the function of which is impaired in many diverse cancers. It has phosphoinositide lipid phosphatase activity by which it suppresses activation of the oncogenic PI3K signalling network but in vitro also displays activity against protein substrates and is able to auto-dephosphorylate its Thr366 residue. Here we generate germline knock-in mice expressing PTEN-Y138L, a mutant enzyme which selectively lacks protein phosphatase activity and retains lipid phosphatase activity. Homozygous PtenY138L/Y138L mice die in utero before E10.5. Primary MEFs and thymocytes with only a single PtenY138L allele display normal low levels of AKT phosphorylation indicating effective regulation of PI3K signalling by endogenous PTEN-Y138L in vivo. Heterozygous Pten+/Y138L mice have reduced overall survival compared to wild type littermates and develop tumours in multiple organs. Our data imply that in addition to its lipid phosphatase activity, the protein phosphatase activity of PTEN is also required for normal embryonic development and tumour suppression.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A mouse model of PTEN Hamartoma Tumour Syndrome reveals that loss of the nuclear function of PTEN drives macrocephaly, lymphoid overgrowth, and late-onset cancer
Priyanka Tibarewal, Victoria Rathbone, … Bart Vanhaesebroeck·Disease Models & MechanismsPeer-reviewed·Nov 11, 2025
- PLEKHS1 drives PI3Ks and remodels pathway homeostasis in PTEN-null prostate
T. A. M. Chessa, P. Jung, … L. R. Stephens·bioRxiv·May 18, 2023
- The lipid phosphatase activity of PTEN dampens FRA1 expression via AKT/mTOR signaling to suppress melanoma
X. Xu, I. Bok, … F. A. Karreth·Cancer ResearchPeer-reviewed·Jan 9, 2024
- The mechanism of full activation of tumor suppressor PTEN at the phosphoinositide-enriched membrane
Hyunbum Jang, Iris Nira Smith, … Ruth Nussinov·iSciencePeer-reviewed·Apr 19, 2021
- Proteomic Analysis of PTEN-Deficient Cells Reveals Src-Mediated Upregulation of EphA2 and Therapeutic Potential of Dual Inhibition
Qiong Wang, Xiangyi Kong, … Xinyan Wu·Molecular & Cellular ProteomicsPeer-reviewed·Oct 22, 2025
- Synthetic essentiality of metabolic regulator PDHK1 in PTEN-deficient cells and cancers
N. Chatterjee, E. Pazarentzos, … T. G. Bivona·bioRxiv·Oct 11, 2018